Journal for ImmunoTherapy of Cancer

Correction: Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial
Journal for ImmunoTherapy of Cancer Jun 2020, 8 (1) e000798corr1; DOI: 10.1136/jitc-2020-000798corr1
Correction: Rhabdomyolysis during high dose interleukin-2 treatment of metastatic melanoma after sequential immunotherapies: a case report
Journal for ImmunoTherapy of Cancer May 2020, 8 (1) e0370-6corr1; DOI: 10.1136/jitc-2020-0370-6corr1
CD244 represents a new therapeutic target in head and neck squamous cell carcinoma
Laura Agresta, Maria Lehn, Kristin Lampe, Rachel Cantrell, Cassandra Hennies, Sara Szabo, Trisha Wise-Draper, Laura Conforti, Kasper Hoebe, Edith M Janssen

Journal for ImmunoTherapy of Cancer Mar 2020, 8 (1) e000245; DOI: 10.1136/jitc-2019-000245
CD3xCD19 DART molecule treatment induces non-apoptotic killing and is efficient against high-risk chemotherapy and venetoclax-resistant chronic lymphocytic leukemia cells
Anne W J Martens, Susanne R Janssen, Ingrid A M Derks, Homer C Adams III, Liat Izhak, Roel van Kampen, Sanne H Tonino, Eric Eldering, Gerritje J W van der Windt, Arnon P Kater

Journal for ImmunoTherapy of Cancer Jun 2020, 8 (1) e000218; DOI: 10.1136/jitc-2019-000218
NKTR-214 immunotherapy synergizes with radiotherapy to stimulate systemic CD8⁺ T cell responses capable of curing multi-focal cancer
Joshua M Walker, Annah S Rolig, Deborah H Charych, Ute Hoch, Melissa J Kasiewicz, Daniel C Rose, Michael J McNamara, Ian F Hilgart-Martiszus, William L Redmond

Journal for ImmunoTherapy of Cancer May 2020, 8 (1) e000464; DOI: 10.1136/jitc-2019-000464
LAG3 (LAG-3, CD223) DNA methylation correlates with LAG3 expression by tumor and immune cells, immune cell infiltration, and overall survival in clear cell renal cell carcinoma
Niklas Klümper, Damian J Ralser, Emma Grace Bawden, Jenny Landsberg, Romina Zarbl, Glen Kristiansen, Marieta Toma, Manuel Ritter, Michael Hölzel, Jörg Ellinger, Dimo Dietrich

Journal for ImmunoTherapy of Cancer Mar 2020, 8 (1) e000552; DOI: 10.1136/jitc-2020-000552
Tocilizumab, but not dexamethasone, prevents CRS without affecting antitumor activity of bispecific antibodies
Joseph Kauer, Sebastian Hörner, Lukas Osburg, Stefanie Müller, Melanie Märklin, Jonas S Heitmann, Latifa Zekri, Hans-Georg Rammensee, Helmut R Salih, Gundram Jung

Journal for ImmunoTherapy of Cancer May 2020, 8 (1) e000621; DOI: 10.1136/jitc-2020-000621
First in human dose calculation of a single-chain bispecific antibody targeting glioma using the MABEL approach
Teilo H Schaller, David J Snyder, Ivan Spasojevic, Patrick C Gedeon, Luis Sanchez-Perez, John H Sampson

Journal for ImmunoTherapy of Cancer Apr 2020, 8 (1) e000213; DOI: 10.1136/jitc-2019-000213
Identification of tumor immune infiltration-associated lncRNAs for improving prognosis and immunotherapy response of patients with non-small cell lung cancer
Jie Sun, Zicheng Zhang, Siqi Bao, Congcong Yan, Ping Hou, Nan Wu, Jianzhong Su, Liangde Xu, Meng Zhou

Journal for ImmunoTherapy of Cancer Feb 2020, 8 (1) e000110; DOI: 10.1136/jitc-2019-000110
CD103+ tumor-resident CD8+ T cell numbers underlie improved patient survival in oropharyngeal squamous cell carcinoma
Rehana Hewavisenti, Angela Ferguson, Kevin Wang, Deanna Jones, Thomas Gebhardt, Jarem Edwards, Mei Zhang, Warwick Britton, Jean Yang, Angela Hong, Umaimainthan Palendira

Journal for ImmunoTherapy of Cancer Jun 2020, 8 (1) e000452; DOI: 10.1136/jitc-2019-000452

Main menu

Journal for ImmunoTherapy of Cancer

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Journal for ImmunoTherapy of Cancer

Pages